Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ALREX

« Back to Dashboard

Summary for Tradename: ALREX

Patents:2
Applicants:1
NDAs:1
Suppliers: see list3

Pharmacology for Tradename: ALREX

Clinical Trials for: ALREX

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
Status: Active, not recruiting Condition: Dry Eyes

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
Status: Active, not recruiting Condition: Meibomian Gland Dysfunction; Posterior Blepharitis

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
Status: Completed Condition: Conjunctivitis

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Completed Condition: Allergic Conjunctivitis

Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Status: Completed Condition: Inflammation; Pain; Cataract

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
Status: Completed Condition: Dry Eye

Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
Status: Completed Condition: Seasonal Allergic Conjunctivitis

Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca
Status: Completed Condition: Keratoconjunctivitis Sicca

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
Status: Completed Condition: Allergic Conjunctivitis

Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Status: Active, not recruiting Condition: Pseudophakia; Inflammation

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
ALREX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020803Mar 9, 1998RXYes5,540,930*PED<disabled>Y<disabled>
Bausch And Lomb
ALREX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020803Mar 9, 1998RXYes5,747,061*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc